ClinicalTrials.gg
Active, not recruitingNCT06765356PROSPECTUpdated Apr 14, 2026

Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias

A Phase 4 interventional study of Farapulse Catheter System and Low-dose Colchicine in Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation and Long-standing Persistent Atrial Fibrillation, sponsored by Vivek Reddy. Active, not recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Vivek Reddy · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
275
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing colchicine in Atrial Fibrillation — 4 open to participants now, 5 under way, 3 of them phase 3. Colchicine · Atrial Fibrillation.

Enrollment
7th of 22
275 · median 236
Started
2025
with 1 other
Phase 4
4 of 22
1 open now
Registered
19th of 22
by date

Among the 22 studies testing colchicine in Atrial Fibrillation, this one is the 7th largest by enrollment, is one of 2 that started in 2025, is one of 4 in phase 4, and was the 19th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

4 of the 22 studies testing colchicine in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About colchicine

Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing colchicine in Atrial Fibrillation, or all of them as a file.
02

Study summary

The purpose of this pragmatic study is to evaluate the safety, performance and effectiveness of the FARAPULSE catheter system (FARAWAVE catheter used in combination with the FARASTAR generator), to treat patients with atrial fibrillation during clinically-indicated ablation procedures

Read the detailed description

By virtue of its efficiency, safety profile, and potential for improved efficacy, there is tremendous excitement about the role of pulsed field ablation (PFA) to treat atrial fibrillation. Indeed, multiple FDA IDE clinical trials on PFA have been, or are being, conducted to treat AF. However, most FDA pivotal trials studying PFA enroll very selected populations and have highly focused inclusion/exclusion criteria and, typically only paroxysmal or persistent AF patients with limited upper age criteria are included, failure of Class I/III AADs is often required, and other disease states that may particularly benefit from PFA (e.g., PFA might be particularly effective in treating HCM pts with their thickened atrial tissue).

In observational European studies of the FARAPULSE catheter system, the technology has proved quite safe and effective in treating most patients with AF. It is a highly efficient ablation system, and can be employed with only deep sedation, and without the need for endotracheal intubation. In addition to the FARAWAVE catheter performing PV isolation and ablation of the posterior left atrium, in the MANIFEST-PF post-approval study of EU experience, the FARAWAVE catheter has also been shown able to create other relevant ablation lesions such as cavo-tricuspid isthmus ablation for typical atrial flutter, or a mitral isthmus line for mitral isthmus flutter.

The FARAWAVE multielectrode pentaspline PFA catheter is the study device. It can be deployed in a basket or flower configuration: 1) Both configurations can be used to isolate PVs, 2) The flower configuration can be used to ablate the posterior wall, and 3) Flower configuration for creation of CTI or Mitral Isthmus Lines.

The ablation procedure will typically follow the below sequence:

  • Pulmonary Vein Isolation (PVI) to be achieved in all patients with atrial fibrillation
  • Posterior wall Ablation: will be used in all persistent/LS-Per AF patients, and as per operator discretion, some paroxysmal AF patients
  • Additional ablation lesion sets are per investigators' discretion:

    • Cavo-tricuspid isthmus line
    • Mitral Isthmus Line
    • Regional fractionation clusters (allowed but not encouraged)
    • Any micro-/macro-reentrant atrial tachycardia's
  • When PFA is performed next to a coronary artery (eg, CTI or mitral isthmus lines), a nitroglycerin pretreatment protocol will be employed as per study protocol.
  • As part of the ablation procedure, any safety assessments that are considered important (e.g., EGD, coronary angiography, etc.) may be performed as per the investigators' discretion; these data will also be collected.
  • For a lesion set that cannot be performed using the FARAPULSE catheter technology, a conventional FDA-approved ablation catheter may be used to complete the procedure as per whatever is optimal for the patient outcome

This study is a prospective, multi-center, non-randomized, investigator-initiated IDE clinical study to determine the safety and efficacy of the recently FDA-approved FARAPULSE system to treat the "usual" patients presenting in clinical practice for catheter ablation of AF. (An IDE is required because the approval for the FARAPULSE system: i) only includes paroxysmal AF patients, and ii) doesn't include the technology's use for linear lesions such as the cavo-tricuspid isthmus line. Participants will be followed for 12-months post-procedure.

There is an optional randomized sub-study looking at the utility of peri-procedural low-dose colchicine in attenuating PFA-related pericardial inflammation and its negative effects (symptoms and atrial arrhythmias). Participants will start low-dose colchicine 5 days prior to PFA procedure and continue up to 3 weeks post-PFA treatment.

03

Conditions studied

  • Persistent Atrial Fibrillation
  • Paroxysmal Atrial Fibrillation
  • Long-standing Persistent Atrial Fibrillation

Browse trials for

Keywords

  • Atrial Fibrillation
  • A-Fib
  • Treatment of Atrial Fibrillation
  • A-Fib Ablation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older
  • Diagnosed with atrial fibrillation with or without concomitant atrial flutter by at some point in the past, and by any criteria (ECG or clear symptoms within the past year)

    • Previous catheter ablation for other arrhythmias (including left-sided ablation, but not for AF) is allowed
  • Planned for a clinically-indicated catheter ablation procedure for managing paroxysmal or persistent atrial fibrillation in accordance with the following recommendations in the ACC/AHA/ACCP/HRS guidelines

    • In patients with symptomatic AF in whom antiarrhythmic drugs have been ineffective, , not tolerated or not preferred, and continued rhythm control is desired, catheter ablation is useful to improve symptoms.(Class 1)
    • In selected patients (generally younger with few comorbidities) with symptomatic paroxysmal AF in whom rhythm control is desired, catheter ablation is useful as therapy to improve symptoms and reduce progression to persistent AF. (Class 1)
    • In patients (other than younger with few comorbidities) with symptomatic paroxysmal or persistent AF who are being managed with a rhythm-control strategy, catheter ablation as first-line therapy can be useful to improve symptoms. (Class 2a)
    • In selected patients with asymptomatic or minimally symptomatic AF, catheter ablation may be useful for reducing progression of AF and its associated complications. (Class 2b)
    • In patients who present with a new diagnosis of HFrEF and AF, arrhythmia-induced cardiomyopathy should be suspected, and an early and aggressive approach to AF rhythm control is recommended. (Class 1)
    • In appropriate patients with AF and HFrEF who are on GDMT, and with reasonable expectation of procedural benefit, catheter ablation is beneficial to improve symptoms, QOL, ventricular function, and cardiovascular outcomes. (Class 1)
    • In appropriate patients with symptomatic AF and HFpEF with reasonable expectation of benefit, catheter ablation can be useful to improve symptoms and improve QOL. (Class 2a)
    • In athletes who develop AF, catheter ablation with PVI is a reasonable strategy for rhythm control because of its effectiveness and low risk of detrimental effect on exercise capacity. (Class 2a)
  • Have in place or have plans for implantation of a loop recorder, pacemaker or cardiac defibrillator capable of recording atrial rhythm (e.g. dual chamber) (ideally, this implantable device would be present for at least 4 weeks pre-PFA)
  • Able and willing to provide written consent and comply with all testing and follow-up requirements

Exclusion criteria

Exclusion Criteria:

  • Documented "active" left atrial thrombus (patients may later undergo the procedure if this is no longer present, eg, with anticoagulation treatment)
  • Reversible cause of AF (e.g., post-operative, thyroid disorder, etc.)
  • Conditions that make an AF ablation procedure unlikely to be successful (e.g., advanced infiltrative cardiomyopathies like amyloid, severe mitral stenosis or regurgitation, and cor pulmonale)
  • PCI/STEMI within the prior 1 month
  • Active systemic infection or sepsis
  • to all anticoagulation
  • Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude an ablation procedure
  • Women who are pregnant, lactating, or who are of childbearing age and plan on becoming pregnant during this trial.
  • or other disease processes likely to limit survival to less than 12 months
  • Currently, enrolled in an study evaluating another device, biologic, or drug, that would interfere with this trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
275 participants (actual)

Study arms

  • Experimental
    Patients with Atrial Fibrillation

    All patients will receive treatment using the Farapulse catheter system (Farawave catheter used in combination with the Farastar generator).

    Device: Farapulse Catheter System · Drug: Low-dose Colchicine

Interventions

  • DeviceFarapulse Catheter System

    The FARAWAVE PFA Catheter is a sterile, single use, over-the-wire, non-deflectable device that is used with the FARASTAR Catheter Connection Cable and FARASTAR Generator to enable delivery of Pulsed Field Ablation energy for irreversible electroporation. The FARAWAVE PFA Catheter has five (5) variably deployable splines. The five splines are undeployed during insertion and removal and during use can deploy continuously from an undeployed state through a partially deployed ("basket-shaped") configuration to a fully deployed ("flower-shaped") configuration with five petals.

  • DrugColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    For participants in the colchicine sub-study, 0.3 mg BID Colchicine. Colchicine will be prescribed to the patient starting 5 days prior to ablation. Patient will continue the colchicine for 3 weeks post-ablation.

06

What researchers measure

Primary outcomes

  1. Number of Acute Procedural Success

    Acute Procedural Success is defined as confirmation of entrance block in all targeted PVs, and acute block of all linear lesions that are attempted (eg, CTI or mitral isthmus line). (The use of a non-study catheter for PVI will be considered an effectiveness failure; however, use of a non-study catheter for ablation unrelated to PVI will be noted, but not considered a treatment failure)

    Time frame: at the end of the procedure (approximately 60 minutes)

Secondary outcomes

  1. Number of Chronic Single-Procedure Success

    Chronic Single-Procedure Success is defined as freedom from all of the following: * Any Detectable AF, AFL or AT; * Any re-ablation for AF, AFL or AT; * Any cardioversion for AF, AFL or AT; * Any use of a non-Failed Class I/III AAD or Amiodarone Where "Detectable AF, AFL or AT" refers to either of the following as recorded by the ICM: * Symptomatic (patient-initiated) recording containing ≥ 30 seconds of continuous AF or AT/AFL * Automatically-detected AF or AT/AFL episodes measured at ≥1 hour in duration (asymptomatic)

    Time frame: up to 12 months post procedure

  2. Number of Participant to Achieve Linear Lesion Bidirectional Block

    Ability to achieve linear lesion bidirectional block using the Farawave catheter alone; for this endpoint, all linear lesions (CTI and Mitral Isthmus) will be aggregated. This will be ascertained acutely after either a 20 min waiting period or despite pharmacologic stress (eg., IV adenosine or IV isoproterenol).

    Time frame: at the end of the procedure (approximately 60 minutes)

  3. Incidence of Primary Adverse Events (PAEs)

    Incidence of Primary Adverse Events (PAEs) (within 7 days of the initial procedure). PAEs include the following AEs: * Atrio-Esophageal Fistula * Phrenic Nerve Paralysis * Cardiac Tamponade/perforation * Pulmonary Vein Stenosis * Death * Stroke/CVA * Major Vascular Access * Complication/Bleeding * Thromboembolism * Myocardial Infarction TIA * Device or procedure related death * pulmonary vein stenosis and atrio-esophageal fistula that occur greater than one week (7 days) post-procedure are also considered and analyzed as primary AEs.

    Time frame: within 7 days of procedure

  4. Number of patients who developed pericarditis

    Number of patients who developed clinical pericarditis within 2 weeks following ablation. This will be ascertained by comprehensive chart review plus at the routine post-ablation follow-up phone visit at 7 days

    Time frame: within 2 weeks from procedure, and at 7 days follow-up visit

  5. Incidence of Serious Adverse Device Effects (SADEs)

    Incidence of Serious Adverse Device Effects (SADEs)

    Time frame: end of study at 12 months

  6. Incidence of Gastrointestinal symptoms

    Incidence of Gastrointestinal symptoms (necessitating cessation of colchicine therapy) for participants in the substudy

    Time frame: end of study at 12 months

  7. Freedom from detectable AF, AFL or AT off AADs

    Freedom from detectable AF, AFL or AT off AADs, defining detectable AF, AFL or AT as Freedom from detectable AF, AFL or AT

    Time frame: end of study 12 months

  8. Number of patients who achieve CT isthmus block

    Number of patients achieving CT isthmus block using the Farawave catheter alone will be recorded.

    Time frame: end of study 12 months

  9. Freedom from persistent AF at 12 months off AADs

    Freedom from persistent AF at 12 months off AADs

    Time frame: end of study 12 months

  10. Freedom from symptomatic AT/AF/AFL recurrence

    Freedom from symptomatic AT/AF/AFL recurrence

    Time frame: end of study 12 months

  11. Change in Blood interleukin-6

    Inflammation is common among those with type 2 diabetes. Inflammatory markers (chemicals in the body that lead to inflammation), such as interleukin-6 (Il-6) have been found to be increased in those with type 2 diabetes For participants in substudy.

    Time frame: 5 days pre-PFA and 48-72 hours post-PFA

  12. Change in C-reactive protein (CRP)

    C-reactive protein (CRP) is produced by the liver. The CRP test is a general test to check for inflammation in the body. It is not a specific test. This means it can reveal that inflammation somewhere in the body, but it cannot pinpoint the exact location or reason. The CRP test is often done with the ESR (erythrocyte or sedimentation rate) test which also looks for inflammation. For participants in substudy.

    Time frame: 5 days pre-PFA and 48-72 hours post-PFA

  13. Changes in Tumor Necrosis Factor (TNF)-α

    Many people take medicines to reduce the immune system's abnormal response. These are called immunosuppressive medicines. Targeted drugs such as tumor necrosis factor (TNF) blockers can be used for some diseases. For participants in substudy.

    Time frame: 5 days pre-PFA and 48-72 hours post-PFA

  14. Changes in Erythrocyte Sedimentation Rate (ESR)

    Erythrocyte sedimentation rate (ESR) is also commonly called a sed rate. It is a test that indirectly measures the level of certain proteins in the blood. This measurement correlates with the amount of inflammation in the body. For participants in substudy.

    Time frame: 5 days pre-PFA and 48-72 hours post-PFA

  15. Brain natriuretic peptide (BNP) levels

    Brain natriuretic peptide (BNP) test is a blood test that measures levels of a protein called BNP that is made by the heart and blood vessels. BNP levels go up when the heart cannot pump the way it should. A result greater than 100 pg/mL is abnormal. The higher the number, the more likely heart failure is present and the more severe it is. For participants in substudy.

    Time frame: 5 days pre-PFA and 48-72 hours post-PFA

  16. Change in durability of lesion sets in any patient that undergoes a second procedure

    Change in Durability of lesion sets in any patient that undergoes a second procedure (block across attempted lines, absence of electrograms in targeted substrate). Observe if the block(s) achieved at the targeted sites from the index procedure have persisted

    Time frame: baseline (index procedure) and end of study 12 months

07

Study locations

9 sites
08

References and documents

Publications

  • Reddy VY, Neuzil P, Koruth JS, Petru J, Funosako M, Cochet H, Sediva L, Chovanec M, Dukkipati SR, Jais P. Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation. J Am Coll Cardiol. 2019 Jul 23;74(3):315-326. doi: 10.1016/j.jacc.2019.04.021. Epub 2019 May 11. PubMed 31085321 ↗
  • Reddy VY, Anter E, Rackauskas G, Peichl P, Koruth JS, Petru J, Funasako M, Minami K, Natale A, Jais P, Nakagawa H, Marinskis G, Aidietis A, Kautzner J, Neuzil P. Lattice-Tip Focal Ablation Catheter That Toggles Between Radiofrequency and Pulsed Field Energy to Treat Atrial Fibrillation: A First-in-Human Trial. Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008718. doi: 10.1161/CIRCEP.120.008718. Epub 2020 May 8. PubMed 32383391 ↗
  • Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, Mountantonakis SE, Gibson DN, Harding JD, Ellis CR, Ellenbogen KA, DeLurgio DB, Osorio J, Achyutha AB, Schneider CW, Mugglin AS, Albrecht EM, Stein KM, Lehmann JW, Mansour M; ADVENT Investigators. Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2023 Nov 2;389(18):1660-1671. doi: 10.1056/NEJMoa2307291. Epub 2023 Aug 27. PubMed 37634148 ↗
  • Reddy VY, Dukkipati SR, Neuzil P, Anic A, Petru J, Funasako M, Cochet H, Minami K, Breskovic T, Sikiric I, Sediva L, Chovanec M, Koruth J, Jais P. Pulsed Field Ablation of Paroxysmal Atrial Fibrillation: 1-Year Outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC Clin Electrophysiol. 2021 May;7(5):614-627. doi: 10.1016/j.jacep.2021.02.014. Epub 2021 Apr 28. PubMed 33933412 ↗
  • Turagam MK, Neuzil P, Schmidt B, Reichlin T, Neven K, Metzner A, Hansen J, Blaauw Y, Maury P, Arentz T, Sommer P, Anic A, Anselme F, Boveda S, Deneke T, Willems S, van der Voort P, Tilz R, Funasako M, Scherr D, Wakili R, Steven D, Kautzner J, Vijgen J, Jais P, Petru J, Chun J, Roten L, Futing A, Lemoine MD, Ruwald M, Mulder BA, Rollin A, Lehrmann H, Fink T, Jurisic Z, Chaumont C, Adelino R, Nentwich K, Gunawardene M, Ouss A, Heeger CH, Manninger M, Bohnen JE, Sultan A, Peichl P, Koopman P, Derval N, Kueffer T, Rahe G, Reddy VY. Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry. Circulation. 2023 Jul 4;148(1):35-46. doi: 10.1161/CIRCULATIONAHA.123.064959. Epub 2023 May 18. PubMed 37199171 ↗
  • Schmidt B, Bordignon S, Neven K, Reichlin T, Blaauw Y, Hansen J, Adelino R, Ouss A, Futing A, Roten L, Mulder BA, Ruwald MH, Mene R, van der Voort P, Reinsch N, Kueffer T, Boveda S, Albrecht EM, Schneider CW, Chun KRJ. EUropean real-world outcomes with Pulsed field ablatiOn in patients with symptomatic atRIAl fibrillation: lessons from the multi-centre EU-PORIA registry. Europace. 2023 Jul 4;25(7):euad185. doi: 10.1093/europace/euad185. PubMed 37379528 ↗
  • Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis AB, Davies DW, Day JD, d'Avila A, de Groot NMSN, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017 Oct;14(10):e275-e444. doi: 10.1016/j.hrthm.2017.05.012. Epub 2017 May 12. No abstract available. PubMed 28506916 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 23 months is below that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2025
First posted
Jan 9, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Mar 30, 2027
CompletionEst.
Mar 30, 2027
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06765356
Lead sponsor
Vivek Reddy
Responsible party
Vivek Reddy (Director, Cardiac Arrhythmia Service, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Jan 9, 2025
Start date
Apr 15, 2025
Primary completion
Mar 30, 2027 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Apr 14, 2026

Study contacts

Vivek Reddy, MD
principal investigator · The Mount Sinai Hospital, Icahn School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion